Sagent Pharmaceuticals Announces Launch of Irinotecan Hydrochloride Injection in Single Dose Vials
Sagent Pharmaceuticals, Inc. (Nasdaq: SGNT) today announced the launch of Irinotecan Injection, the generic form of the chemotherapy drug Camptosar®, in two latex free, preservative free single dose vials. According to IMS data for the twelve-months ended March 2012, the U.S. market for Irinotecan approximated $28 million. As with all products in Sagent's portfolio, Irinotecan features the company's PreventIV Measures^SM packaging and labeling designed to aid in the reduction of medication errors.
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.